Company Overview

Cabaletta Bio, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing engineered cell therapies for autoimmune diseases. The company operates within the biotechnology and immunology sectors, with a primary emphasis on precision cellular immunotherapies designed to selectively reset or eliminate pathogenic immune cells. Cabaletta Bio’s core technology platforms are centered on chimeric antigen receptor (CAR) T-cell therapies and engineered T-cell approaches intended to treat autoimmune disorders with high unmet medical need. Its lead programs target diseases such as myositis, systemic sclerosis, lupus nephritis, generalized myasthenia gravis, and other B cell-mediated autoimmune conditions.

The company’s primary revenue drivers remain research and development activities and capital raised through equity financing, as Cabaletta Bio has not yet commercialized products. A major strategic differentiator is its focus on applying CAR T-cell technologies—traditionally developed for oncology—to autoimmune diseases using its “deep reset” therapeutic concept aimed at durable immune reprogramming. Cabaletta Bio was founded in 2017 and emerged from research conducted at the University of Pennsylvania, particularly work associated with advances in cellular immunotherapy and B-cell targeting technologies. The company became publicly traded on the Nasdaq under the ticker CABA in 2019.

Business Operations

Cabaletta Bio conducts operations primarily through integrated clinical development and research functions in the United States. The company’s business model centers on discovering, developing, and clinically advancing autologous engineered T-cell therapies. Its principal development programs include the rese-cel platform, including CABA-201, a fully human CD19-CAR T-cell investigational therapy being studied across multiple autoimmune indications. The company’s operational activities include preclinical research, clinical trial management, regulatory engagement, manufacturing coordination, and intellectual property development.

The company controls proprietary technology assets associated with engineered immune cell therapies and maintains collaborations connected to manufacturing and clinical development. Cabaletta Bio has historically relied on contract manufacturing organizations and specialized cell therapy infrastructure to support clinical supply production. Its intellectual property portfolio includes licenses and rights related to CAR T-cell engineering technologies originally associated with the University of Pennsylvania ecosystem. Operations are concentrated domestically, though clinical and scientific activities may involve international research and manufacturing partners commonly used within the biotechnology industry.

Strategic Position & Investments

Cabaletta Bio’s strategic direction is focused on establishing engineered cellular therapies as a transformative treatment approach for autoimmune disease. A central growth initiative is the advancement of CABA-201 across multiple indications under a shared development strategy targeting B cell-driven autoimmune conditions. The company has emphasized clinical expansion into diseases where current standards of care rely heavily on chronic immunosuppression and where durable remission remains difficult to achieve. Its development strategy leverages lessons from oncology CAR T-cell therapy while adapting treatment protocols for autoimmune patient populations.

The company has invested significantly in clinical-stage development, translational medicine capabilities, and manufacturing readiness to support multicenter clinical studies. Cabaletta Bio’s pipeline also includes additional programs involving engineered T-cell technologies and immune-cell modulation approaches. The company’s strategic positioning is strengthened by scientific associations with leading academic immunology and cell therapy researchers, particularly within the University of Pennsylvania network. Public disclosures and investor materials indicate ongoing prioritization of scalable manufacturing, regulatory engagement, and clinical data generation as key drivers of long-term value creation.

Geographic Footprint

Cabaletta Bio is headquartered in Philadelphia, Pennsylvania, and its operational footprint is primarily concentrated in the United States. The company conducts clinical development activities through collaborations with academic medical centers, clinical trial sites, and specialized treatment institutions across major U.S. healthcare markets. Its research ecosystem is closely connected to the broader biotechnology and cell therapy infrastructure in the Philadelphia region.

Although Cabaletta Bio does not currently maintain a broad commercial international presence, its activities are linked to the global biotechnology supply chain through manufacturing vendors, scientific collaborations, and regulatory engagement common to advanced cell therapy development. The company’s clinical ambitions position it within the broader global autoimmune therapeutics market, particularly in the rapidly expanding field of engineered immune-cell therapies across North America and potentially Europe in future development phases.

Leadership & Governance

Cabaletta Bio was founded by biotechnology and academic leaders associated with advances in immunology and cell therapy research. The company’s governance and strategic vision emphasize translating precision cellular immunotherapies into potentially durable treatments for autoimmune diseases. Leadership communications have consistently focused on clinical execution, scientific rigor, and expanding the therapeutic applicability of CAR T-cell technology beyond oncology.

Key executives and leadership figures include:

• Steven Nichtberger, M.D. – Chairman and Co-Founder
• David J. Chang, M.D. – Chief Executive Officer
• Francis Cuss, M.B. B.Chir., FRCP – Chief Scientific Officer
• Jason N. Adler – Chief Financial Officer
• Aimee Gavulic – Chief Operating Officer
• Katharine Knobil, M.D. – Member of the Board of Directors

The company operates under a governance structure typical of publicly traded biotechnology firms, with oversight from a board of directors and executive leadership responsible for clinical strategy, capital allocation, regulatory compliance, and pipeline advancement. Public disclosures, including SEC filings, indicate continued emphasis on disciplined clinical development and long-term shareholder value creation through differentiated autoimmune cell therapy programs.